Japanese drugmaker Takeda (TYO: 4502) posted revenue of 4.58 trillion yen ($31.7 billion) for the fiscal year ended March 31, ...

Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% increase Product Revenues in the first in the first ...

Immunosuppressants represent a second-line treatment option for refractory moderate-to-severe ulcerative colitis, particularly for patients who are either unresponsive to glucocorticoids or dependent ...

Vedolizumab is an integrin receptor antagonist that specifically targets the gastrointestinal tract, reducing inflammation without systemic immunosuppression. The VERDICT trial, an interim analysis of ...

Obesity was associated with lower odds of steroid-free clinical remission in patients with inflammatory bowel disease (IBD) at week 24 after the initiation of treatment. "In clinical practice, it ...

Although anti-tumor necrosis factor (TNF)-α drugs “retained their central position in the armamentarium,” the authors said, there was also an increase in prescriptions of non–anti-TNF biologics, ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Entyvio contains the active ingredient vedolizumab. Entyvio is ...